Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director comp.
Acq. announced
Appointed director
Ocuphire Pharma, Inc. (OCUP) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/27/2023 8-K Quarterly results
08/11/2023 8-K Quarterly results
08/01/2023 8-K Quarterly results
06/02/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "Third Amendment to Second Amended and Restated Bylaws of Ocuphire Pharma, Inc"
05/15/2023 8-K Investor presentation, Quarterly results
Docs: "End-of-Phase 2 Meeting with FDA Anticipated in 2H 2023 to Confirm Phase 3 Regulatory Path for Oral APX3330 in Diabetic Retinopathy PDUFA date for Nyxol First Indication in Reversal of Pharmacologically-Induced Mydriasis Set for September 28, 2023; Nyxol Development and Commercialization Funded by Viatris",
"Corporate Presentation"
04/21/2023 8-K Quarterly results
03/30/2023 8-K Quarterly results
01/25/2023 8-K Investor presentation
Docs: "Investor Presentation Materials",
"[email protected]"
12/06/2022 8-K Quarterly results
11/07/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "License and Collaboration Agreement by and between Ocuphire Pharma, Inc. and Famy",
"Conference Call Tomorrow November 8, 2022 at 8:30 AM ET"
11/04/2022 8-K Quarterly results
10/14/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
08/12/2022 8-K Investor presentation, Quarterly results
Docs: "Positive Results from Phase 3 LYNX-1 Trial of Nyxol in Night Vision Disturbances Mark Sixth Positive Nyxol Clinical Data Readout Across Multiple Indications Data Expected in 2H 2022 from Phase 2b Trial of APX3330, a Potential First-in-Class Oral Treatment for Diabetic Retinopathy",
"Corporate Presentation"
06/17/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
05/19/2022 8-K Quarterly results
05/13/2022 8-K Quarterly results
04/28/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Ocuphire Completes Last Clinical Trial Supporting the Planned 2022ndA Submission with the Announcement of Positive Results from MIRA-4 Pediatric Safety Trial Evaluating Nyxol ® for Reversal of Mydriasis"
03/29/2022 8-K Investor presentation
Docs: "Investor Presentation Materials",
"Ocuphire Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol ® in the Reversal of Mydriasis"
03/24/2022 8-K Quarterly results
Docs: "Building Momentum with Completion of Patient Enrollment in 4 Late-Stage Trials"
01/31/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Presentation Materials"
01/31/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Led by KOLs Paul Karpecki, O.D., F.A.A.O. and Mitchell Jackson, M.D. ● Nyxol met its primary endpoint in its first Phase 3 RM registration trial demonstrating statistically significant rapid reversal of dilation with an alpha-1 adrenergic blocker MOA uniquely suited to avoid the narrow-angle and other safety issues associated with cholinergic drug reversal of dilations ● With an opportunity to impact over 100 million eye dilations annually for routine eye exams, surgical procedures, and retina treatments, pre-commercial activities are underway to support the potential launch of Nyxol in RM in 2023 led by Bindu Manne, Ocuphire’s recently appointed Head of Market Development and Commercialization Session III: Nyxol in Presbyopia Led by KOLs Jay Pepose, M.D., Ph.D. and James Katz,..."
01/05/2022 8-K Investor presentation
Docs: "Initiated Enrollment in MIRA-4 Pediatric Trial in Reversal of Mydriasis: Ocuphire recently enrolled the first subjects in MIRA-4, which is a randomized, double-masked, placebo-controlled study of Nyxol eye drops to reverse pharmacologically-induced mydriasis in healthy pediatric subjects. Approximately 20 pediatric subjects ages 3 to 11 will be enrolled with safety as the primary objective and efficacy as secondary objectives. Nyxol has the potential to address an estimated $500 million reversal of dilation market across pediatrics and adults, which has no current commercially available therapies. Completed Enrollment of LYNX-1study in Night Vision Disturbances: Enrollment has been completed in the LYNX-1 Phase 3 clinical trial investigating Nyxol for the treatment of NVD. LYNX-1 is a rand...",
"Corporate Presentation"
08/12/2021 8-K Investor presentation, Quarterly results
Docs: "Ocuphire Announces Financial Results for the Second Quarter 2021 and Provides Corporate Update",
"Corporate Presentation"
06/30/2021 8-K Quarterly results
06/23/2021 8-K Quarterly results
06/08/2021 8-K Quarterly results
06/07/2021 8-K/A Quarterly results
06/04/2021 8-K Quarterly results
05/07/2021 8-K Quarterly results
04/12/2021 8-K Quarterly results
03/15/2021 8-K Quarterly results
03/11/2021 8-K Quarterly results
03/11/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy